COMMUNIQUÉS West-GlobeNewswire

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
20/07/2026
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
20/07/2026
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]
Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026
20/07/2026
New data from the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 NOUS-209 is an off-the-shelf [...]
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
20/07/2026
MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on [...]
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
20/07/2026
SOUTH ORANGE, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced today that President [...]
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
20/07/2026
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen - derived treatments for [...]
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
20/07/2026
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the [...]
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
20/07/2026
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non- [...]
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
20/07/2026
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER [...]
ColestZen Official Launch 2026 - Natural Cholesterol Support Supplement for Adults (US, UK, Canada, and Australia)
20/07/2026
The ColestZen Official Store has introduced ColestZen, a dietary supplement formulated with ingredients selected to support healthy cholesterol levels, help maintain blood sugar levels already within the normal range, [...]
Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
20/07/2026
REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of [...]
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
20/07/2026
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, [...]
Vireo Growth Inc. to Acquire Certain Assets of The Cannabist Company Holdings Inc.
20/07/2026
Enters definitive agreement that expands its operations in one market and enters four additional states MINNEAPOLIS, July 20, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “ [...]
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
20/07/2026
● As of July 18, 2026, net asset value (NAV 1 ) per share was $66.16 ● As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion 2 . Nes-Ziona, Israel, July 20, 2026 ( [...]
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
20/07/2026
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
20/07/2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Frishantic Launches Chelated Magnesium Glycinate for Nighttime Calm and Daily Muscle Ease
20/07/2026
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Frishantic today announced the launch of Frishantic Magnesium Glycinate , a chelated magnesium glycinate supplement designed for consumers seeking nighttime relaxation support [...]
Cytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of Directors
20/07/2026
Luba Greenwood joins Cytosurge’s Board of Directors to support the company’s next phase of commercial growth and scientific progress as Cytosurge builds the causal data foundation for AI-driven drug discovery. ZURICH, [...]
CLINUVEL’s ADS to commence trading on Nasdaq
20/07/2026
CUVL to trade on the highest tier – Global Select Market MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is [...]

Pages